A5054058644- Diabetes Management and Research
- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Metabolism, Diabetes, and Cancer
- Diet and metabolism studies
- Mobile Health and mHealth Applications
- Fibroblast Growth Factor Research
- Pharmaceutical studies and practices
- Diabetes Management and Education
- Pulmonary Hypertension Research and Treatments
- Medication Adherence and Compliance
- Pharmacology and Obesity Treatment
- ECG Monitoring and Analysis
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Angiogenesis and VEGF in Cancer
- Botulinum Toxin and Related Neurological Disorders
- Wireless Body Area Networks
- Growth Hormone and Insulin-like Growth Factors
- Neurological and metabolic disorders
- Hormonal Regulation and Hypertension
- Intramuscular injections and effects
- Artificial Intelligence in Healthcare
- Cancer Cells and Metastasis
AMCR Institute
2016-2025
Headlands Center for the Arts
2024-2025
Adelphi Group (United Kingdom)
2024
Bavarian Nordic (Denmark)
2021
University of California, San Diego
2011-2020
Ferris State University
2020
Reckitt Benckiser (United States)
2018
Brampton Civic Hospital
2016
Diabeteszentrum Bad Lauterberg
2013
Bristol-Myers Squibb (Germany)
2011
<h3>Importance</h3> Weight loss improves cardiometabolic risk factors in people with overweight or obesity. Intensive lifestyle intervention and pharmacotherapy are the most effective noninvasive weight approaches. <h3>Objective</h3> To compare effects of once-weekly subcutaneous semaglutide, 2.4 mg vs placebo for management as an adjunct to intensive behavioral therapy initial low-calorie diet adults <h3>Design, Setting, Participants</h3> Randomized, double-blind, parallel-group, 68-week,...
Introduction: The purpose of the study was to evaluate performance and usability FreeStyle® Libre™ Flash glucose monitoring system (Abbott Diabetes Care, Alameda, CA) for interstitial results compared with capillary blood results. Materials Methods: Seventy-two participants type 1 or 2 diabetes were enrolled by four U.S. clinical sites. A sensor inserted on back each upper arm up 14 days. Three factory-only calibrated lots used in study. Sensor measurements (BG) (approximately eight per day)...
The safety and effectiveness of the in-home use a hybrid closed-loop (HCL) system that automatically increases, decreases, suspends insulin delivery in response to continuous glucose monitoring were investigated.Adolescents (n = 30, ages 14-21 years) adults 94, 22-75 with type 1 diabetes participated multicenter (nine sites United States, one site Israel) pivotal trial. Medtronic MiniMed® 670G was used during 2-week run-in phase without HCL control, or Auto Mode, enabled (Manual Mode) and,...
Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure high cortisol concentrations. Our objective was evaluate the safety efficacy of mifepristone, glucocorticoid receptor antagonist, in endogenous CS. We conducted 24-wk multicenter, open-label trial after failed multimodality therapy at 14 U.S. academic medical centers three private research centers. Participants included 50 adults CS type 2 diabetes mellitus/impaired glucose...
OBJECTIVE—Hypoglycemia and wide glucose excursions continue to be major obstacles achieving target HbA1c values the associated reductions in long-term complications (and economic costs) people with insulin-treated diabetes. In this study we evaluated accuracy, safety, clinical effectiveness of a continuous glucose-sensing device.
Underutilization of glucose data and lack easy standardized collection, analysis, visualization, guided clinical decision making are key contributors to poor glycemic control among individuals with type 1 diabetes. An expert panel diabetes specialists, facilitated by the International Diabetes Center sponsored Helmsley Charitable Trust, met in 2012 discuss recommendations for standardization analysis presentation monitoring data, initial focus on derived from CGM systems. The members were...
Aim: The aim of this study was to compare the efficacy and safety once-daily human glucagon-like peptide-1 analogue liraglutide with dipeptidyl peptidase-4 inhibitor sitagliptin, each added metformin, over 52 weeks in individuals type 2 diabetes. Methods: In an open-label, parallel-group trial, metformin-treated participants were randomised 1.2 mg/day (n = 225), 1.8 221) or sitagliptin 100 219) for 26 (main phase). Participants continued same treatment a 26-week extension. Results:...
OBJECTIVE Evaluate the efficacy and safety of dual sodium–glucose cotransporter 1 (SGLT1) SGLT2 inhibitor sotagliflozin in combination with optimized insulin type diabetes (T1D). RESEARCH DESIGN AND METHODS The inTandem1 trial, a double-blind, 52-week phase 3 randomized North American adults T1D to placebo (n = 268), 200 mg 263), or 400 262) after 6 weeks optimization. primary end point was HbA1c change from baseline at 24 weeks. HbA1c, weight, were also assessed through 52 RESULTS From mean...
<h3>Importance</h3> Hypoglycemia, common in patients with type 1 diabetes, is a major barrier to achieving good glycemic control. Severe hypoglycemia can lead coma or death. <h3>Objective</h3> To determine whether insulin degludec noninferior superior glargine U100 reducing the rate of symptomatic hypoglycemic episodes. <h3>Design, Setting, and Participants</h3> Double-blind, randomized, crossover noninferiority trial involving 501 adults at least risk factor treated 84 US 6 Polish centers...
Background: A composite metric for the quality of glycemia from continuous glucose monitor (CGM) tracings could be useful assisting with basic clinical interpretation CGM data. Methods: We assembled a data set 14-day 225 insulin-treated adults diabetes. Using balanced incomplete block design, 330 clinicians who were highly experienced analysis and ranked best to worst glycemia. used principal component multiple regressions develop model predict clinician ranking based on seven standard...
To evaluate the safety of in-home use MiniMed™ 670G system with SmartGuard™ technology in children type 1 diabetes (T1D).Participants (N = 105, ages 7-13 years, mean age 10.8 ± 1.8 years) were enrolled at nine centers (eight United States and one Israel) completed a 2-week baseline run-in phase Manual Mode followed by 3-month study Auto enabled. Sensor glucose (SG), glycated hemoglobin (HbA1c), percentage SG values across ranges, variability, during phases compared. Participants underwent...
Background: We evaluated the accuracy and safety of a seventh generation (G7) Dexcom continuous glucose monitor (CGM) during 10.5 days use in adults with diabetes. Methods: Adults either type 1 or 2 diabetes (on intensive insulin therapy not) participated at 12 investigational sites United States. In-clinic visits were conducted on 2, 4 7, second half day 10 first 11 for frequent comparisons comparator blood measurements obtained YSI 2300 Stat Plus analyzer. Participants wore sensors...
Comparing the performance of different continuous glucose monitoring (CGM) systems is challenging due to lack comprehensive guidelines for clinical study design. In particular, absence concise requirements distribution comparator (reference) blood (BG) concentrations and their rate change (RoC) that are used evaluate CGM performance, impairs comparability. For this article, several experts in field testing have collaborated propose characteristics measurements should be collected during...
Background: Real-time continuous glucose monitoring (CGM) was studied in 140 adults with diabetes over a 12-week period of home use. Hemoglobin A1c (HbA1c) measured on day 1 (baseline) and at weeks 6 12. Methods: On 1, participants received the CGM device (STS® System, DexCom, Inc., San Diego, CA) underwent training proper Insertion first sensor performed under staff supervision. Subjects inserted subsequent sensors their own. After calibration, (a 3-day sensor, receiver, transmitter)...
Background: We assessed the performance of a modified Dexcom G4 Platinum system with an advanced algorithm, in comparison frequent venous samples measured on laboratory reference (YSI) during clinic session and to self-monitored blood glucose (SMBG) home use. Methods: Fifty-one subjects diabetes were enrolled prospective multicenter study. Subjects wore 1 sensor for 7-day use participated one 12-hour in-clinic day 1, 4, or 7 collect YSI every 15 minutes capillary SMBG test 30 minutes....
The efficacy of automatic suspension insulin delivery in induced hypoglycemia among subjects with type 1 diabetes was evaluated.In this randomized crossover study, used a sensor-augmented pump system low glucose suspend (LGS) feature that automatically stops for 2 h following sensor (SG) value ≤70 mg/dL. Subjects fasted overnight and exercised until their plasma (measured the YSI 2300 STAT Plus™ lactate analyzer [YSI Life Sciences, Yellow Springs, OH]) reached ≤85 mg/dL on different...
Underutilization of glucose data and lack easy standardized collection, analysis, visualization, guided clinical decision making are key contributors to poor glycemic control among individuals with type 1 diabetes mellitus. An expert panel specialists, facilitated by the International Diabetes Center sponsored Helmsley Charitable Trust, met in 2012 discuss recommendations for standardizing analysis presentation monitoring data, initial focus on derived from continuous systems. The members...
Cleared blood glucose monitors (BGMs) for personal use may not always deliver levels of accuracy currently specified by international and U.S. regulatory bodies. This study's objective was to assess the 18 such systems cleared Food Drug Administration representing approximately 90% commercially available used from 2013 2015.A total 1,035 subjects were recruited have a capillary (BG) level measured on six different reference sample prepared plasma testing at laboratory. Products obtained...
Persistent use of real-time continuous glucose monitoring (CGM) improves diabetes control in individuals with type 1 (T1D) and 2 (T2D).PRECISE II was a nonrandomized, blinded, prospective, single-arm, multicenter study that evaluated the accuracy safety implantable Eversense CGM system among adult participants T1D T2D (NCT02647905). The primary endpoint mean absolute relative difference (MARD) between paired Yellow Springs Instrument (YSI) reference measurements through 90 days postinsertion...
Background: Use of continuous glucose monitoring (CGM) systems can improve glycemic control, but widespread adoption CGM utilization has been limited, in part because real and perceived problems with accuracy reliability. This study compared performance metrics for a new-generation system those previous-generation device. Subjects Methods: were enrolled 7-day, open-label, multicenter pivotal study. Sensor readings venous YSI measurements (blood analyzer from Inc., Yellow Springs, OH) every...